Intravenous sodium valproate aborts migraine headaches rapidly

Acta Neurologica Scandinavica

Volumn 123, Issue 4, 2011, Pages 257-265

  Shahien, R ^a   Saleh, S A ^a   Bowirrat, A ^a  

^a Rebecca Sieff Government Hospital   (Israel)

Author keywords

Dihydroergotamine; Efficacy; Migraine headache; Safety; Sodium valproate; Triptans

Indexed keywords

VALPROIC ACID;

ADULT; ANALGESIA; ARTICLE; CLINICAL ARTICLE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; INFORMED CONSENT; MALE; MAXIMUM PLASMA CONCENTRATION; MIGRAINE; OUTCOME ASSESSMENT; PAIN; PATIENT SATISFACTION; PHOTOPHOBIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE; VOMITING;

ADULT; FEMALE; GABA AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; TREATMENT OUTCOME; VALPROIC ACID; YOUNG ADULT;

EID: 79952087735     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01394.x     Document Type: Article

References (59)

1. Lipton RB, Stewart WF. Migrane in the United States: a review of epidemiology and health care use. Neurology 1993;43:S6-10.
2. Lipton RB, Bigal ME, Diamond M et al. Migraine prevalence, disease burden, and the need for prevalence therapy. Neurology 2007;68:343-9.
3. Stewart W, Lipton R, Celentano D, Reed M. Prevalence of migraine headache in the United states: relation to age, income, race, and other sociodemographic factors. JAMA 1992;267:64-9.
4. Tepper SJ. A pivotal moment in 50years of headache history: the first American migraine study. Headache 2008;48:730-2.
5. Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache 1986;26:168-71.
6. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991;265:2831-5.
7. Mathew NT, Dexter J, Couch J et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. Arch Neurol 1992;49:1271-6.
8. Carpay HA, Matthijsse P, Steinbuch M, Mulder PG. Oral and subcutaneous sumatriptan in the acute treatment of migraine: an open randomized cross-over study. Cephalalgia 1997;17:591-5.
9. Klapper JA, Stanton JS. Ketorolac vesus DHE and metoclopramide in the treatment of migraine headaches. Headache 1991;31:523-4.
10. Kelly KM. Cardiac arrest following use of sumatriptan. Neurology 1995;45:1211-3.
11. Silberstein SD, Young WB. Analgesic rebound headache. How great is the problem and what can be done Drug Saf 1995;13:133-44.
12. Freitag FG, Collins SD, Carlson HA et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002;58:1652-9.
13. Cutrer FM, Limmroth V, Moskowitz MA. Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia 1997;17:93-100.
14. Hering R, Steiner TJ. Sodium valproate for acute migraine attacks. Cephalalgia 1994;14:305-6.
15. Mathew NT, Kailasam J, Meadors L, Chernyschev O, Gentry P. Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report. Headache 2000;40:720-3.
16. Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache 2001;41:976-80.
17. Tanen DA, Miller S, French T, Riffenburgh RH. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann Emerg Med 2003;41:847-53.
18. Leniger T, Pageler L, Stude P, Diener HC, Limmroth V. Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. Headache 2005;45:42-6.
19. Norton J. Use of intravenous valproate sodium in status migraine. Headache 2000;40:755-7.
20. Schwartz TH, Karpitskiy VV, Sohn RS. Intravenous valproate sodium in the treatment of daily headache. Headache 2002;42:519-22.
21. Stillman MJ, Zajac D, Rybicki LA. Treatment of primary headache disorders with intravenous valproate: initial outpatient experience. Headache 2004;44:65-9.
22. Cutrer FM, Moskowitz MA. Wolff Award 1996. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache 1996;36:579-85.
23. Storer RJ, Akerman S, Goadsby PJ. GABA receptors modulate trigeminovascular nociceptive neurotransmission in the trigeminocervical complex. Br J Pharmacol 2001;134:896-904.
24. Thomaides T, Karapanayiotides T, Kerezoudi E et al. Intravenous valproate aborts glyceryl trinitrateinduced migraine attacks: a clinical and quantitative EEG study. Cephalalgia 2008;28:250-6.
25. Sorensen KV. Valpoate: a new drug in migraine prophylaxis. Acta Neurol Scand 1988;78:346-8.
26. Ghose K, Niven B. Prophylactic sodium valproate in patients with drug-resistant migraine. Methods Find Exp Clin Pharmacol 1998;20:353-9.
27. Dlener HC, Kaube H, Ummroth V. A practical guide to the management and prevention of migraine. Drugs 1998;56:811-24.
28. Nishikawa T, Scatton B. Inhibitory influence of nuclei as the neuroanatomical site of GABAergic inhibition of cerebral serotonergic neurons. Brain Res 1985;331:91-103.
29. Cutrer FM, Limmroth V, Ayata G, Moskowitz MA. Valproate reduces c-fos expression in trigeminal nucleus caudalis (TNC) after noxious meningeal stimulation [abstract]. Cephalalgia 1995;14:96.
30. Cutrer FM, Moskowitz MA. The actions of valproate and neurosteroids in a model of trigeminal pain. Headache 1996;36:265.
31. Capendeguy O, Horisberger JD. Functional effects of Na+, K+-ATPase gene mutations linked to familial hemiplegic migraine. Neuromolecular Med 2004;6:105-16.
32. Hildreth CJ, Lynm C, Glass RM. Migraine headache. JAMA 2009;301:24.
33. Cholet N, Pellerin L, Magistretti PJ, Hamel E. Similar perisynaptic glial localization for the Na+, K+-ATPase alpha 2 subunit and the glutamate transporters GLAST and GLT-1 in the rat somatosensory cortex. Cereb Cortex 2002;12:515-25.
34. Chuquet J, Hollender L, Nimchinsky EA. High-resolution in vivo imaging of the neurovascular unit during spreading depression. J Neurosci 2007;27:4036-44.
35. Clausen T. Potassium and sodium transport and pH regulation. Can J Physiol Pharmacol 1992;70(Suppl):S219-22.
36. Anselmi B, Baldi E, Casacci F, Salmon S. Endogenous opioids in cerebrospinal fluid and blood in idiopathic headache sufferers. Headache 2005;20:294-9.
37. Hardebo JE, Ekman R, Eriksson M. Low CSF Met-enkephalin levels in cluster headache are elevated by acupuncture. Headache 2005;29:494-7.
38. Mosnaim AD, Wolf ME, Chevesich J, Callaghan OH, Diamond S. Plasma methionine enkephalin levels - a biological marker for migraine? Headache 2005;25:259-67.
39. Mulleners WM, Chronicle EP, Vredeveld JW, Koehler PJ. Visual cortex excitability in migraine before and after valproate prophylaxis: a pilot study using TMS. Eur J Neurol 2002;9:35-40.
40. Cutrer FM, Limmroth V, Ayata G, Moskowitz MA. Attenuation by valproate of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Br J Pharmacol 1995;116:3199-204.
41. Silberstein SD, Lipton RB, Goadsby P. Headache in clinical practice. Oxford, UK: Isis Medical Media, Ltd, 1998.
42. Loscher W, Vetter M. In vivo effects of aminooxyacetic acid and valproic acid on nerve terminal (synaptosomal) GABA levels in discrete brain areas of the rat. Correlation to pharmacological activities. Biochem Pharmacol 1985;34:1747-56.
43. Lee WS, Limmroth V, Ayata C et al. Peripheral GABAA receptor-mediated effects of sodium valproate on dural plasma extravasations to substance P and trigeminal stimulation. Br J Pharmacol 1995;116:1661-7.
44. Loscher W. Valproate induced changes in GABA metabolism at the subcellular level. Biochem Pharmacol 1985;34:1747-56.
45. Mathew NT, Saper JR, Silberstein SD et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52:281-6.
46. Erdemoglu AK, Ozbakir S. Valproic acid in prophylaxis of refractory migraine. Acta Neurol Scand 2000;102:354-8.
47. 1B/1D receptor agonists. Arch Neurol 2002;59:1084-8.
48. Johnson KW, Phebus LA, Cohen ML. Serotonin in migraine: theories, animal models and emerging therapies. Prog Drug Res 1998;51:219-44.
49. Robbins LR. Intravenous sodium injection for prolonged migraine headache. Am J Pain Manag 2001;11:5-7.
50. Loscher W. Valporate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 1999;58:31-59.
51. Loscher W. Effect of inhibitors of GABA transaminase on the synthesis, binding, uptake and metabolism of GABA. J Neurochem 1980;34:1603-8.
52. Zeise ML, Kasparow S, Zieglgansberger W. Volproate suppresses N-methyl-D-aspartate evoked, transient depolarizations in the rat neocortex in vitro. Brain Res 1991;544:345-8.
53. Loscher W, Fisher JE, Nau H, Honack D. Marked increase in anticonvulsant activity but decrease in wet-dog shake behavior during short-term treatment of amygdale-kindled rats with valproic acid. Eur J Pharmacol 1988;150:221-32.
54. Petty F. GABA and mood disorders: a brief review and hypothesis. J Affect Disord 1995;34:275-81.
55. Biggs CS, Pearce BR, Fowler LJ, Whitton PS. Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study. J Neurochem 1992;59:1702-8.
56. Mubhoff U, Madeja M, Ousing R, Speckmann EJ. Valporate affects glutamate but not GABA receptors. Eur J Neurosci 1996;9:205.
57. Maneesh Gupta M, Annadatha S. Treating bipolar disorder in patients with renal failure having haemodialysis: two case reports. Clin Pract Epidemiol Ment Health 2008;4:21.
58. Krusz JC. Intravenous valproate sodium in the treatment of intractable migraines in the headache clinic, (poster presented at 10th Int'l Headache Congress, New York June, 2001). Cephalalgia 2001;21:433.
59. Caruso JM, Brown WD, Exil G, Gascon GG. The efficacy of divalproex sodium in the prophylactic treatment of children with migraine. Headache 2000;40:672-6.